25-Nov-2025 7:00 AM CST - Business Wire Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the companys management team will participate in two upcoming conferences. 8th Annual Evercore Healthcare Conference Date: December 2, 2025 Time: 8:45-9:05 am ET Format: Fireside Chat Participant: Dr. Arun Swaminathan, Ph.D., Chief
12-Nov-2025 7:00 AM CST - Business Wire Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter ended September 30, 2025. Recent Corporate Highlights Published a study in Frontiers in Immunology linking inflammation and oxidative stress to the progression of Park
18-Jun-2025 7:15 AM CST - Business Wire Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 25, 2025 Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Event: iAccess Alpha Virtual Best Ideas Summer Conference Date: June 24, 2025 Time: 10:30am ET (presentation) Webcast: https://www
16-May-2025 9:53 AM CST - Business Wire Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in the H.C. Wainwright 3rd Annual BioConnect Conference being held in New York City on Tuesday, May 20, 2025. Chief Executive Officer Arun Swaminathan, Ph.D. will participate in a fireside chat and be available for one-on-one meetings throughout the event.
13-May-2025 7:00 AM CST - Business Wire Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2025. Recent Corporate Highlights Announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose (LD) IL-2 and CTLA4-Ig combination treatment in pa
18-Mar-2025 7:15 AM CST - Business Wire Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024. Corporate Highlights FY2024 to Date Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Ph
25-Feb-2025 7:15 AM CST - Business Wire Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimers Disease Using GLP-1 Agonists and Combinations Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast Is Alzheimers next for GLP-1s and Combos? on February 27, 2025 to discuss the potential treatment of Al
4-Feb-2025 7:15 AM CST - Business Wire Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held February 11-12, 2025 in a virtual format. Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference Presentation Date: Tuesda
25-Nov-2024 7:15 AM CST - Business Wire Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7th Annual Evercore HealthCONx Conference being held on December 3 5, 2024 at the Loews Coral Gables Hotel in Coral Gables, FL. On Tuesday, December 3 at 12:55
25-Nov-2025 7:00 AM CST - Business Wire Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the companys management team will participate in two upcoming conferences. 8th Annual Evercore Healthcare Conference Date: December 2, 2025 Time: 8:45-9:05 am ET Format: Fireside Chat Participant: Dr. Arun Swaminathan, Ph.D., Chief
12-Nov-2025 7:00 AM CST - Business Wire Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter ended September 30, 2025. Recent Corporate Highlights Published a study in Frontiers in Immunology linking inflammation and oxidative stress to the progression of Park
18-Jun-2025 7:15 AM CST - Business Wire Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 25, 2025 Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Event: iAccess Alpha Virtual Best Ideas Summer Conference Date: June 24, 2025 Time: 10:30am ET (presentation) Webcast: https://www
16-May-2025 9:53 AM CST - Business Wire Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in the H.C. Wainwright 3rd Annual BioConnect Conference being held in New York City on Tuesday, May 20, 2025. Chief Executive Officer Arun Swaminathan, Ph.D. will participate in a fireside chat and be available for one-on-one meetings throughout the event.
13-May-2025 7:00 AM CST - Business Wire Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2025. Recent Corporate Highlights Announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose (LD) IL-2 and CTLA4-Ig combination treatment in pa
18-Mar-2025 7:15 AM CST - Business Wire Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024. Corporate Highlights FY2024 to Date Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Ph
25-Feb-2025 7:15 AM CST - Business Wire Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimers Disease Using GLP-1 Agonists and Combinations Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast Is Alzheimers next for GLP-1s and Combos? on February 27, 2025 to discuss the potential treatment of Al
4-Feb-2025 7:15 AM CST - Business Wire Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held February 11-12, 2025 in a virtual format. Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference Presentation Date: Tuesda
25-Nov-2024 7:15 AM CST - Business Wire Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7th Annual Evercore HealthCONx Conference being held on December 3 5, 2024 at the Loews Coral Gables Hotel in Coral Gables, FL. On Tuesday, December 3 at 12:55
